Save
Email
Print
ShareMar. 12, 2010 — Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.
Their findings have been published in the journal Nature Immunology. The work has been carried out by a team at the MRC Toxicology Unit at the University of Leicester.
Dr Melania Capasso, one of the authors of the study, described the findings as being 'very significant'.
"We showed that a newly discovered protein, HVCN1, regulates antibody production through modulation of intracellular oxidation. In the absence of HVCN1, the immune response is blunted. These findings are very novel and significantly contribute to our understanding of how the organism mounts an immune response.
"The findings are very significant for the immunology field and help elucidate the contribution of natural oxidants such as reactive oxygen species to B cell activation and represent the rationale for using HVCN1 as a target for therapies where activation of B cell needs to be diminished."
Dr Capasso said the findings could be useful for the treatment of some types of B cell lymphoma and the treatment of autoimmune diseases such as Lupus (and rheumatoid arthritis).
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by University of Leicester, via AlphaGalileo.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Capasso et al. HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nature Immunology, 2010; 11 (3): 265 DOI: 10.1038/ni.1843
Note: If no author is given, the source is cited instead.
more 
